Summit Creek Advisors LLC raised its stake in Dolby Laboratories (NYSE:DLB – Free Report) by 24.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 125,034 shares of the electronics maker’s stock after acquiring an additional 24,905 shares during the quarter. Summit Creek Advisors LLC’s holdings in Dolby Laboratories were worth $9,049,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently modified their holdings of the company. Allworth Financial LP grew its stake in shares of Dolby Laboratories by 590.4% during the second quarter. Allworth Financial LP now owns 504 shares of the electronics maker’s stock valued at $37,000 after purchasing an additional 431 shares during the last quarter. Mather Group LLC. acquired a new position in Dolby Laboratories during the 3rd quarter worth $38,000. Ameritas Advisory Services LLC bought a new position in Dolby Laboratories in the 2nd quarter valued at $48,000. Atlantic Union Bankshares Corp acquired a new stake in shares of Dolby Laboratories in the 2nd quarter valued at $50,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of Dolby Laboratories during the second quarter worth $60,000. 58.56% of the stock is currently owned by institutional investors and hedge funds.
Dolby Laboratories Trading Up 1.2%
Shares of DLB opened at $64.37 on Monday. The stock has a market cap of $6.15 billion, a P/E ratio of 24.48 and a beta of 0.88. Dolby Laboratories has a 1 year low of $63.05 and a 1 year high of $89.66. The stock’s 50-day moving average price is $65.95 and its two-hundred day moving average price is $70.11.
Dolby Laboratories Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Wednesday, December 10th. Shareholders of record on Tuesday, December 2nd were issued a $0.36 dividend. This represents a $1.44 annualized dividend and a yield of 2.2%. This is a boost from Dolby Laboratories’s previous quarterly dividend of $0.33. The ex-dividend date was Tuesday, December 2nd. Dolby Laboratories’s dividend payout ratio (DPR) is 54.75%.
Insider Activity
In other Dolby Laboratories news, SVP Shriram Revankar sold 3,000 shares of Dolby Laboratories stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $65.55, for a total transaction of $196,650.00. Following the transaction, the senior vice president directly owned 67,435 shares in the company, valued at approximately $4,420,364.25. The trade was a 4.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP John D. Couling sold 7,273 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $68.75, for a total value of $500,018.75. Following the completion of the transaction, the senior vice president directly owned 108,065 shares of the company’s stock, valued at approximately $7,429,468.75. The trade was a 6.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 162,120 shares of company stock valued at $10,906,559. 37.93% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the company. Rosenblatt Securities decreased their price target on Dolby Laboratories from $95.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, November 19th. Barrington Research cut their target price on shares of Dolby Laboratories from $100.00 to $95.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 19th. Wall Street Zen upgraded shares of Dolby Laboratories from a “hold” rating to a “buy” rating in a research report on Monday, January 5th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Dolby Laboratories in a research note on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Dolby Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $92.00.
Check Out Our Latest Research Report on Dolby Laboratories
Dolby Laboratories Company Profile
Dolby Laboratories, Inc is a global leader in audio and imaging technologies, specializing in the development, licensing and deployment of solutions that enhance entertainment and communications experiences. The company’s core business revolves around creating advanced audio codecs, noise reduction systems and spatial sound technologies for a wide range of applications, including cinema, broadcast, gaming, streaming and personal devices. Dolby’s licensing model enables consumer electronics manufacturers, content creators and service providers to integrate its technologies into products such as televisions, smartphones, home theater systems and set-top boxes.
Among its flagship innovations are Dolby Atmos, an immersive audio format that delivers three-dimensional soundscapes for theaters and home systems; Dolby Digital and Dolby Digital Plus, widely adopted audio compression formats for broadcast and streaming; and Dolby Vision, a high-dynamic-range imaging technology that expands color, contrast and brightness in displays.
Further Reading
- Five stocks we like better than Dolby Laboratories
- Wall Street ‘Sleeper Stock’ Could Become #1 Stock of 2026
- Do not delete, read immediately
- Trump Planning to Use Public Law 63-43: Prepare Now
- Huge robotics rollout underway
- How a Family Trust May Be Able To Help Preserve Your Wealth
Want to see what other hedge funds are holding DLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dolby Laboratories (NYSE:DLB – Free Report).
Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
